Quoin Pharmaceuticals CEO Michael Myers Acquired A Total Of 37,894 ADSs At Prices Ranging From $0.619-$0.7974 Per ADS. Similarly, COO Denise Carter Acquired A Total Of 37,735 ADSs At Prices Between $0.6253-$0.7965 Per ADS
Quoin Pharmaceuticals CEO Michael Myers Acquired A Total Of 37,894 ADSs At Prices Ranging From $0.619-$0.7974 Per ADS. Similarly, COO Denise Carter Acquired A Total Of 37,735 ADSs At Prices Between $0.6253-$0.7965 Per ADS
Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction.
Quoin Pharmicals（納斯達克股票代碼：QNRX）是一家臨床階段、專注於開發和商業化罕見病和孤兒病新療法的專業製藥公司。該公司今天宣佈，其首席執行官邁克爾·邁爾斯和首席運營官丹妮絲·卡特最近大量收購了該公司的美國存托股票（ADS），這表明他們對公司的增長和方向充滿信心。
On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. These insider purchases reflect the leadership's strong confidence in Quoin's growth trajectory and commitment to delivering long-term value to shareholders as the company advances its mission to address unmet needs in underserved patient populations globally.
2024年9月3日和4日，Quoin Pharmicals首席執行官邁克爾·邁爾斯共收購了37,894張ADS，價格從每張ADS0.619美元到0.7974美元不等。同樣，首席運營官丹尼斯·卡特在2024年9月3日至4日期間共收購了37,735張ADS，價格在每份廣告0.6253美元至0.7965美元之間。這些內幕收購反映了領導層對Quoin增長軌跡的堅定信心，以及在公司推進其解決全球服務不足患者群體未滿足需求的使命的過程中，爲股東創造長期價值的承諾。
